Evidence map›Paper›PMID 37649304›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study.

Paarth B Dodhiawala, Kyle Pribyl, Jared Larson, Victor Vakayil, Malavika Chandrashekar, Amanda Lord, Julie Welbig, Nicole D Zantek, David Martin, James V Harmon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Expert Opinion on Implementing Oral Anticoagulation Reversal Protocols in US Hospitals.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Paarth B DodhiawalaMedical Scientist Training Program, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-6362-5847
Kyle PribylDepartment of Anesthesia, University of Minnesota, Minneapolis, MN, USA.
Jared LarsonDepartment of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA.
Victor VakayilDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Malavika ChandrashekarDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Amanda LordDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
Julie WelbigLaboratory Administration, Fairview Health Services, St. Paul, MN, USA.
Nicole D ZantekDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
David MartinDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
James V HarmonDepartment of Surgery, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USUniversity of Minnesota Medical Center · USFairview Health Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The administration of 4-factor prothrombin complex concentrate (4F-PCC) has expanded beyond its Food and Drug Administration (FDA)-approved indication for the emergent reversal of vitamin K antagonists (VKAs). Therefore, this study aimed to evaluate the risks and benefits associated with the expanded use of 4F-PCC. We conducted a single-center retrospective review of 4F-PCC administrations at our university hospital. Of the 159 patients who received 4F-PCC, 76% (n = 121) and 24% (n = 38) received it for the FDA-approved indication in the vitamin K-related coagulopathy (VKA) group and for expanded use in the nonvitamin K-related coagulopathy (nVKA) group, respectively. The expanded use of 4F-PCC was associated with a less robust reduction in the international normalized ratio (INR) (INR of -0.7 ± 1.3 vs INR of -1.6 ± 1.8,

Indexed as

Blood Coagulation DisordersLiver DiseasesAnticoagulantsBlood Coagulation FactorsFactor IXHumansInternational Normalized RatioRetrospective StudiesVitamin KAnticoagulantsBlood Coagulation FactorsFactor IXprothrombin complex concentratesVitamin K4-factor prothrombin complex concentrate4F-PCCcoagulopathyliver diseasenonvitamin K antagonist

Identifiers

PMID37649304
PMCPMC10475228
OpenAlexW4386306315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.